SUBSCRIBE
SUBSCRIBE

ALX Oncology

NEWS
Business
BioSpace Movers & Shakers, May 8
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
May 7, 2020
 · 
5 min read
 · 
Alex Keown
Load More
JOBS
IN THE PRESS
Press Releases
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
 · 
13 min read
Press Releases
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
May 7, 2026
 · 
7 min read
Press Releases
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
April 30, 2026
 · 
3 min read
Press Releases
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - April 17, 2026
April 20, 2026
 · 
1 min read
Press Releases
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
April 14, 2026
 · 
4 min read
Press Releases
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 1, 2026
 · 
15 min read
Press Releases
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
February 19, 2026
 · 
2 min read
Press Releases
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
February 19, 2026
 · 
1 min read
Press Releases
ALX Oncology Announces Pricing of Underwritten Offering - January 30, 2026
February 1, 2026
 · 
4 min read
Press Releases
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
February 1, 2026
 · 
4 min read
Load More